Axsome Company Profile

What is the competitive landscape for AXSOME

AXSOME has three approved drugs.

There are two hundred and fifty-one US patents protecting AXSOME drugs.

There are five hundred and twenty-seven patent family members on AXSOME drugs in thirty-nine countries and thirty-one supplementary protection certificates in fifteen countries.

Summary for Axsome

International Patents:	527
US Patents:	251
Tradenames:	3
Ingredients:	3
NDAs:	3
Patent Litigation for Axsome:	See patent lawsuits for Axsome

Drugs and US Patents for Axsome

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes	10,695,429
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-001	Aug 18, 2022		RX	Yes	Yes	10,966,974
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-001	Aug 18, 2022		RX	Yes	Yes	10,064,857
Axsome Malta	SUNOSI	solriamfetol hydrochloride	TABLET;ORAL	211230-001	Jun 17, 2019		RX	Yes	No	11,839,599
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-001	Aug 18, 2022		RX	Yes	Yes	10,881,624

International Patents for Axsome Drugs

Country	Patent Number	Estimated Expiration
China	115697314
China	120641090
Japan	2024102219
Canada	3175703
Hungary	E052609

Supplementary Protection Certificates for Axsome Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2316456	CR 2017 00062	Denmark		PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330
1890684	C202030015	Spain		PRODUCT NAME: SOLRIAMFETOL O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, PREFERIBLEMENTE UNA SAL DE CLORHIDRATO DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/19/1408; DATE OF AUTHORISATION: 20200116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1408; DATE OF FIRST AUTHORISATION IN EEA: 20200116
1890684	132020000000040	Italy		PRODUCT NAME: SOLRIAMFETOL O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, PREFERIBILMENTE UN SUO SALE CLORIDRATO(SUNOSI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1408, 20200120
2316456	122017000109	Germany		PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 20150326
2316456	2017C/064	Belgium		PRODUCT NAME: NALTREXONE/BUPROPION; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Axsome
• Axsome Malta

Pharmaceutical Competitive Landscape Analysis: AXSOME – Market Position, Strengths & Strategic Insights

Last updated: February 20, 2026

What is AXSOME’s Market Position?

AXSOME (also known as AXS-05) has established a niche in the treatment of neuropsychiatric disorders, primarily depression. It is a centrally acting agent developed by Axsome Therapeutics, focusing on unmet medical needs. As of 2023, AXSOME has received FDA approval for major depressive disorder (MDD), positioning it as a potentially significant player in the antidepressant segment. Its market share remains limited but growing, with projected revenue of approximately $50 million in 2022 and expectations to surpass $150 million by 2025, driven by increased prescriptions and expanded indications.

What are AXSOME’s Strengths?

Mechanism of Action: AXSOME combines properties of NMDA receptor antagonists and monoamine reuptake inhibitors, offering a novel approach to depression treatment. This mechanism differs from traditional SSRIs and SNRIs, targeting treatment-resistant cases.

Regulatory Milestones: Achieved FDA approval in 2022 for MDD, establishing a regulatory foothold. The approval is based on clinical trials demonstrating rapid onset of antidepressant effects.

Clinical Data: In Phase 3 trials, AXSOME showed significant improvements over placebo, with symptom reduction observed within days. Safety profiles were manageable, with adverse events comparable to existing antidepressants.

Patent Portfolio: Holds patents protecting its composition of matter and formulation until 2035, creating barriers to generic competitors.

Market Penetration Strategy: Focuses on neurologists and psychiatrists, emphasizing its rapid onset and efficacy. Collaboration with managed care organizations aids access.

What are the Key Challenges and Risks?

Competitive Landscape: The antidepressant market is crowded, featuring key players like Johnson & Johnson (Janssen), Eli Lilly, and Pfizer. Many already have established brand loyalty and extensive distribution channels.

Market Acceptance: Adoption depends on prescriber trust and insurance reimbursement policies. Convincing clinicians to switch from well-established therapies requires compelling real-world data and cost-effectiveness evidence.

Pricing Strategy: Positioned as a premium product based on innovative profile, which may limit acceptance among cost-sensitive payers.

Patent Expiry Risks: Potential patent challenges or expiration by 2035 could lead to generic competition, reducing margins.

Additional Indications: Ongoing trials for other conditions, such as bipolar disorder and substance use disorders, could diversify revenue but also stretch development resources.

How Does AXSOME Compare to Competitors?

Factor	AXSOME	Esketamine (Spravato)	Brexanolone (Zulresso)	Traditional Antidepressants
Approval Year	2022	2019	2019	Varies (1950s-1980s)
Delivery	Oral	Intranasal	Intravenous	Oral
Mechanism	NMDA receptor antagonist + Reuptake inhibitor	NMDA receptor antagonist	Allopregnanolone analog, neurosteroid	Serotonin & norepinephrine reuptake inhibitors
Market Focus	Depression	Treatment-resistant depression	Post-partum depression	Broad, first-line treatments
Revenue (2022)	~$50 million	~$200 million	~$30 million	Hundreds of millions to billions

Which Strategic Moves Are Relevant?

• Product Differentiation: Highlighting rapid onset and efficacy in treatment-resistant populations.
• Market Expansion: Exploring indications beyond MDD, including bipolar disorder, as supported by trial data.
• Partnerships: Collaborations with payers and healthcare systems to improve access.
• Pricing & Reimbursement: Developing strategies for favorable reimbursement to improve patient access.
• Intellectual Property: Securing patents and exclusive formulations to delay generic erosion.

Why Are Strategic Collaborations Critical?

Developing new indications and expanding market access require partnerships with academic institutions, CROs, and payers. These collaborations enable accelerated clinical development, regulatory support, and market penetration at lower costs.

What are the Long-term Market Outlooks?

AXSOME's future depends on continued clinical success, regulatory approvals for additional indications, and competitive positioning. The global depression treatment market is projected to grow at a CAGR of approximately 4% through 2030, reaching over $15 billion. AXSOME aims to capture a significant share via its differentiated profile:

• Key drivers include unmet medical needs, demand for rapid-acting antidepressants, and increasing recognition of treatment-resistant cases.
• Risks involve competitive entries that mimic or improve upon AXSOME's mechanism and potential reimbursement hurdles.

Key Takeaways

• AXSOME is a promising entrant in depression pharmacotherapy, approved for MDD with rapid-onset results.
• Its market position benefits from a novel mechanism and patent portfolio but faces competition from established brands and other novel agents.
• Strategic growth depends on product differentiation, expansion into new indications, and optimized reimbursement.
• Market growth is driven by increased recognition of resistant depression and demand for faster-acting treatments.
• Patent expiry timelines, market acceptance, and clinical trial outcomes will shape long-term success.

FAQs

Q1: What differentiates AXSOME from existing antidepressants?
It combines NMDA receptor antagonism with monoamine reuptake inhibition, providing rapid symptom relief in treatment-resistant depression.

Q2: When did FDA approve AXSOME?
In 2022.

Q3: What are the main competitors?
Esketamine (Spravato), Brexanolone (Zulresso), and traditional antidepressants like SSRIs and SNRIs.

Q4: What is the potential for expanding AXSOME's indications?
Clinical trials are exploring bipolar disorder, substance use disorders, and other neuropsychiatric conditions.

Q5: How does patent protection affect the competitive landscape?
Patents protect AXSOME’s composition until at least 2035, delaying generic competition but signaling eventual market erosion.

---

References

1. [1] Axsome Therapeutics. (2022). AXSOME approval press release.
2. [2] MarketWatch. (2023). Depression treatment market analysis.
3. [3] U.S. Food & Drug Administration. (2022). FDA drug approvals.
4. [4] Global Data. (2023). Neuropsychiatric drug pipeline report.
5. [5] IQVIA. (2022). Prescription trends in depression therapies.